Eloxx enters $3.2M debt amendment with Hercules and Domicilium; Royalty obligations up to $53M

Eloxx Pharmaceuticals, Inc.

Tranche 2 Advance of $3.175M provided under Sixth Amendment to Hercules loan; Bridge Loan of $288k also made.
Conversion options: Tranche 1A/1B debt can convert into equity if Qualified Financing ≥$7M occurs before April 2025.
Royalty Agreement: 33% of first three Almirall milestones and 25% of subsequent milestones, capped at $53M, plus 0.75% of ELX-02 and 0.50% of ZKN-013 revenue.
Amended Securities Purchase Agreement grants anti-dilution rights to SD MF for 15 months.
Reporting covenant for FY2023 audited financials extended to November 29, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.